FGFR2 (N549K)
Sign in to save this workspaceFGFR2 · Variant type: point · HGVS: p.N549K
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Futibatinib | 99.7% | 0.3% | 98.48 |
| 2 | Selpercatinib | 99.1% | 0.9% | 96.72 |
| 3 | Vandetanib | 98.5% | 1.5% | 95.74 |
| 4 | Canertinib | 92.2% | 7.8% | 96.49 |
| 5 | Erlotinib | 91.2% | 8.8% | 99.75 |
| 6 | Erdafitinib | 90.6% | 9.4% | 95.71 |
| 7 | Pralsetinib | 90.4% | 9.6% | 93.43 |
| 8 | Sunitinib | 87.3% | 12.7% | 91.73 |
| 9 | Infigratinib | 86.9% | 13.1% | 98.24 |
| 10 | Pemigatinib | 86.2% | 13.8% | 98.23 |
| 11 | Alpelisib | 83.3% | 16.7% | 97.22 |
| 12 | Fedratinib | 82.7% | 17.3% | 96.21 |
| 13 | Tivozanib | 82.5% | 17.5% | 92.42 |
| 14 | Repotrectinib | 79.2% | 20.8% | 84.21 |
| 15 | Entrectinib | 67.5% | 32.5% | 93.69 |
| 16 | Pexidartinib | 66.0% | 34.0% | 99.49 |
| 17 | Pacritinib | 58.7% | 41.3% | 88.64 |
| 18 | Gilteritinib | 58.2% | 41.8% | 88.97 |
| 19 | Tenalisib | 53.6% | 46.4% | 97.98 |
| 20 | Defactinib | 49.1% | 50.9% | 92.68 |
| 21 | Ripretinib | 44.9% | 55.1% | 92.95 |
| 22 | Deucravacitinib | 35.0% | 65.0% | 98.99 |
| 23 | Sorafenib | 31.5% | 68.5% | 96.72 |
| 24 | Avapritinib | 31.5% | 68.5% | 97.73 |
| 25 | Upadacitinib | 21.9% | 78.1% | 97.98 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Futibatinib | 99.7% | 99.3% | +0.4% |
| Selpercatinib | 99.1% | 95.0% | +4.1% |
| Vandetanib | 98.5% | 90.8% | +7.7% |
| Canertinib | 92.2% | — | — |
| Erlotinib | 91.2% | — | — |
| Erdafitinib | 90.6% | 99.0% | -8.4% |
| Pralsetinib | 90.4% | 93.2% | -2.8% |
| Sunitinib | 87.3% | — | — |
| Infigratinib | 86.9% | 98.8% | -11.9% |
| Pemigatinib | 86.2% | 98.7% | -12.5% |
| Alpelisib | 83.3% | 98.9% | -15.6% |
| Fedratinib | 82.7% | — | — |
| Tivozanib | 82.5% | — | — |
| Repotrectinib | 79.2% | 79.8% | -0.6% |
| Entrectinib | 67.5% | 81.5% | -14.0% |
| Pexidartinib | 66.0% | — | — |
| Pacritinib | 58.7% | — | — |
| Gilteritinib | 58.2% | — | — |
| Tenalisib | 53.6% | 96.0% | -42.4% |
| Defactinib | 49.1% | — | — |
| Ripretinib | 44.9% | 85.4% | -40.5% |
| Deucravacitinib | 35.0% | 92.5% | -57.5% |
| Sorafenib | 31.5% | — | — |
| Avapritinib | 31.5% | — | — |
| Upadacitinib | 21.9% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_upper_aerodigestive_tract | Brain/CNS | ref |
| carcinoma_endometrium | Uterus | ref |
| carcinoma_urinary_tract | Biliary Tract | ref |
| carcinoma_breast | Breast | ref |
| carcinoma_ovary | Ovary | ref |
| carcinoma_lung | Lung | ref |
| carcinoma_stomach | Stomach/Digestive Tract | ref |
| other_endometrium | Uterus | ref |
| carcinoma_oesophagus | Stomach/Digestive Tract | ref |
| adnexal_tumour_skin | Skin | ref |
| carcinoma_small_intestine | Small Intestine | ref |
| carcinoma_biliary_tract | Biliary Tract | ref |
| other_bone | Bone | ref |
| BLCA-CN | Bladder | ref |
| BLCA-US | Bladder | ref |
| BRCA-EU | Breast | ref |
| BRCA-US | Breast | ref |
| GACA-JP | Stomach/Digestive Tract | ref |
| LUAD-US | Lung | ref |
| UCEC-US | Uterus | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 24.0ms